IP Library Granted Patent US 8,877,780
Granted Patent B2
US 8,877,780 · App. 12/130,445 · Granted Nov 4, 2014

5-substituted isoindoline compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,877,780
App. No.
12/130,445
Granted
Nov 4, 2014
Kind
B2
Abstract

This invention relates to 5-substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

Claims (14)

1. A compound of formula (III):

or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof, wherein:

X is CH 2 or C═O;

Y is O or S;

R 10 is:

(C 1 -C 10 )alkyl; (C 1 -C 10 )alkoxy;

(C 0 -C 10 )alkyl-(5 to 10 membered heteroaryl or heterocycle), said heteroaryl or heterocycle optionally substituted with one or more of (C 1 -C 6 )alkyl, itself substituted with one or more halogen; halogen; oxo; (C 1 -C 6 )alkoxy, itself substituted with one or more halogen; or —Z—(C 1 -C 6 )alkyl, wherein Z is S or SO 2 , and wherein said (C 1 -C 6 )alkyl may be optionally substituted with one or more halogen;

(C 0 -C 10 )alkyl-(5 to 10 membered aryl), said aryl optionally substituted with one or more of: halogen; (C 1 -C 6 )alkoxy, itself optionally substituted with one or more halogen; (C 1 -C 6 )alkyl, itself optionally substituted with one or more halogen; or —Z—(C 1 -C 6 )alkyl, wherein Z is S or SO 2 , and wherein said (C 1 -C 6 )alkyl may be optionally substituted with one or more halogen; or

(C 1 -C 6 )alkyl-CO—O—R 12 , wherein R 12 is H or (C 1 -C 6 )alkyl; and

R H is H or (C 1 -C 6 )alkyl.

2. The compound of claim 1 , which is:

3. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 .

4. A single unit dosage form comprising a compound of claim 1 .

5. The single unit dosage form of claim 4 , which is suitable for oral or parenteral administration.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2011
From: ZHANG, WEIHONG; KHALIL, EHAB M.
To: CELGENE CORPORATION
Reel/Frame 025791/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2008
From: MULLER, GEORGE W.; CHEN, ROGER S. C.; RUCHELMAN, ALEXANDER L.
To: CELGENE CORPORATION
Reel/Frame 021470/0376 →